Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
AuthorSchellens, J. H. M.
Cox, E. H.
Loos, W. J.
Hanauske, A. R.
Google Scholar check
MetadataShow full item record
Population pharmacokinetic-dynamic analysis was prospectively integrated in the clinical phase II programme of EO9 to determine the population pharmacokinetic profile in a larger population of patients, to estimate individual patient pharmacokinetic parameters, and to investigate relationships between drug exposure and clinical outcome. A sparse sampling method was developed, which involved three sampling times, and was implemented during course 1. A Bayesian algorithm was used to estimate individual pharmacokinetic parameters, in particular total plasma clearance (CL) of EO9 and area under the curve (AUC). In total, samples were collected of 85 (65%) of the patients. Pharmacokinetic evaluation was successful in 61 (72%) of the sampled patients. CL of EO9 showed substantial variability (median 5.08 l/min; range 2.67-6.42) and was of the same magnitude as in the phase I study where full pharmacokinetic profiles were used. No significant relationships were noticed between exposure parameters and safety, but overall limited toxicity was observed. No tumor responses were documented. Prospective implementation of large-scale population pharmacokinetic-dynamic analysis is feasible and may generate important findings, in particular when tumor responses and relevant toxicity are observed. © 2001 Lippincott Williams & Wilkins.
Showing items related by title, author, creator and subject.
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: A Hellenic Cooperative Oncology Group (HeCOG) study Kalofonos, H. P.; Nikolaides, C.; Samantas, E.; Mylonakis, N.; Aravantinos, Gerasimos; Dimopoulos, M. A.; Gennatas, Constantinos; Kouvatseas, G.; Giannoulis, E.; Dervenis, C.; Basdanis, G.; Pavlidis, Nicholas; Androulakis, G.; Fountzilas, George (2002)We conducted a phase III study in patients with advanced colorectal carcinoma (ACC). The total number of patients randomized from October 1993 until July 1998 was 192, whereas therapy was started on 179 and 158 (82.3%) ...
A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG) Pavlidis, Nicholas; Hanauske, A. R.; Gamucci, T.; Smyth, J. F.; Lehnert, M.; Velde, A. Te; Lan, J.; Verweij, J. (1996)In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bioreductive alkylating indoloquinone. The drug was ...
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG) Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...